Article info

Download PDFPDF
Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities

Authors

  • Yao-Chun Hsu School of Medicine, I-Shou University, Kaohsiung, TaiwanCenter for Liver Diseases, E-Da Hospital, Kaohsiung, Taiwan PubMed articlesGoogle scholar articles
  • Cheng-Hao Tseng School of Medicine, I-Shou University, Kaohsiung, TaiwanGastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan PubMed articlesGoogle scholar articles
  • Tung-Hung Su Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanHepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Jia-Horng Kao Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanHepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Mindie H Nguyen Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USAEpidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Yao-Chun Hsu, Center for Liver Diseases, E-Da Hospital, Kaohsiung 824, Taiwan; holdenhsu{at}ntu.edu.tw
View Full Text

Citation

Hsu Y, Tseng C, Su T, et al
Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities

Publication history

  • Received September 30, 2021
  • Accepted October 3, 2021
  • First published October 20, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.